{"id":1055108,"date":"2012-09-13T01:15:48","date_gmt":"2012-09-13T01:15:48","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/novel-non-antibiotic-agents-against-mrsa-and-common-strep-infections.php"},"modified":"2024-08-17T19:10:09","modified_gmt":"2024-08-17T23:10:09","slug":"novel-non-antibiotic-agents-against-mrsa-and-common-strep-infections-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/novel-non-antibiotic-agents-against-mrsa-and-common-strep-infections-2.php","title":{"rendered":"Novel non-antibiotic agents against MRSA and common strep infections"},"content":{"rendered":"<p><p>Public  release date: 12-Sep-2012  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Jessica Studeny    <a href=\"mailto:jessica.studeny@case.edu\">jessica.studeny@case.edu<\/a>    216-368-4692    Case    Western Reserve University<\/p>\n<p>    Menachem Shoham, PhD, associate professor of biochemistry at    Case Western Reserve University School of Medicine, has    discovered novel antivirulence drugs that, without killing the    bacteria, render Methicillin Resistant Staphylococcus    Aureus (MRSA) and Streptococcus pyogenes, commonly    referred to as strep, harmless by preventing the production of    toxins that cause disease. The promising discovery was    presented this week at the Interscience Conference on    Antimicrobial Agents and Chemotherapy in San Francisco.  <\/p>\n<p>    MRSA infections are a growing public health concern, causing    20,000 to 40,000 deaths per year in the United States alone. It    is the most prevalent bacterial pathogen in hospital settings    and in the community at large, with about one million    documented infections per year nationally, costing an estimated    $8 billion annually to treat.  <\/p>\n<p>    The problem has become increasingly severe as the bacteria have    developed a resistance to antibiotics. As result, health care    providers are running out of options to treat patients    suffering from antibiotic-resistant infections, like MRSA and    strep, creating a dire need for alternative treatments and    approaches.  <\/p>\n<p>    \"Staph bacteria are ubiquitous and normally do not cause    infections, however, occasionally these bacteria become harmful    due to their secretion of toxins,\" says Dr. Shoham. \"We have    discovered potential antivirulence drugs that block the    production of toxins, thus rendering the bacteria harmless.    Contrary to antibiotics, these new antivirulence drugs do not    kill the bacteria. Since the survival of the bacteria is not    threatened by this approach, the development of resistance,    like that to antibiotics, is not anticipated to be a serious    problem.\"  <\/p>\n<p>    Dr. Shoham identified a bacterial protein, known as AgrA, as    the key molecule responsible for turning on the release of    toxins. AgrA, however, needs to be activated to induce toxin    production. His goal was to block the activation of AgrA with a    drug, thus preventing the cascade of toxin release into the    blood that can lead to serious infections throughout the body.  <\/p>\n<p>    The screening for AgrA inhibitors was initially carried out in    a computer by docking libraries of many thousands of    \"drug-like\" compounds and finding out which compounds would fit    best into the activation site on AgrA. Subsequently, about 100    of the best scoring compounds were tested in the laboratory for    inhibition of the production of a toxin that ruptures red blood    cells. Seven of these compounds were found to be active.    Testing compounds bearing chemical similarity to the original    compounds lead to the discovery of additional and more potent    so-called \"lead\" compounds.  <\/p>\n<p>    Optimization of the initial \"lead\" compounds was performed by    chemical synthesis of 250 new compounds bearing small but    important chemical modifications on one of the initial leads.    More than a dozen active compounds have been discovered by this    method. The best drug candidate reduces red blood cell rupture    by 95 percent without affecting bacterial growth.  <\/p>\n<p>    Beginning this fall, Dr. Shoham and colleagues will begin    testing the drug candidate in animal models.  <\/p>\n<\/p>\n<p>More:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2012-09\/cwru-nna091212.php\" title=\"Novel non-antibiotic agents against MRSA and common strep infections\" rel=\"noopener\">Novel non-antibiotic agents against MRSA and common strep infections<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Public release date: 12-Sep-2012 [ | E-mail | Share ] Contact: Jessica Studeny <a href=\"mailto:jessica.studeny@case.edu\">jessica.studeny@case.edu<\/a> 216-368-4692 Case Western Reserve University Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) and Streptococcus pyogenes, commonly referred to as strep, harmless by preventing the production of toxins that cause disease. The promising discovery was presented this week at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/novel-non-antibiotic-agents-against-mrsa-and-common-strep-infections-2.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577469],"tags":[],"class_list":["post-1055108","post","type-post","status-publish","format-standard","hentry","category-biochemistry"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1055108"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1055108"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1055108\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1055108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1055108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1055108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}